# JUN 13 2005

# 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS BNP Assay for Bayer ADVIA Integrated Modular System (IMS)

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and 21 CFR 807.92.

The assigned 510(k) number is: k051265

# June 6,2005

# 1. Submitter's name, address and telephone number:

Andres Holle   
Manager,Regulatory Affairs   
Bayer HealthCare LLC   
A subsidiary of Bayer Corporation   
511 Benedict Avenue   
Tarrytown,NY 10591   
TEL:914-524-2531   
FAX:914-524-2500   
Email: andres.holle.b@bayer.com

# 2. Name of the device:

a) Classification Names: B-type natriuretic peptide test systems, S862.1117 Classification: Class I Product Code: NBC

b) Common name: BNP assays

c)Proprietary name:

ADVIA Immuno Modular System (IMS)@ B-Type Natriuretic Peptide (BNP) Assay

d） The device:

<table><tr><td rowspan=1 colspan=1>Product Name</td><td rowspan=1 colspan=1>Reagent Part#/BAN Number</td><td rowspan=1 colspan=1>CalibratorPart#/BAN Number</td></tr><tr><td rowspan=1 colspan=1>ADVIA IMS BNP Assay</td><td rowspan=1 colspan=1>0154537(100 tests)</td><td rowspan=1 colspan=1>00155177</td></tr></table>

3．Predicate Device:

<table><tr><td rowspan=1 colspan=1>Product Name</td><td rowspan=1 colspan=1>Reagent Part #</td><td rowspan=1 colspan=1>Master CurveMaterial Part#</td></tr><tr><td rowspan=1 colspan=1>ADVIA Centaur BNP Assay</td><td rowspan=1 colspan=1>REF02816634(500 tests)REF02816138(100 tests)</td><td rowspan=1 colspan=1>REF02815905</td></tr></table>

# 4. Description of the device:

The ADVIA IMS BNP Assay is an in vitro immunoassay intended for the quantitative measurement of b-type natriuretic peptide (BNP) in human EDTA plasma covering the analytical range of 10 to approximately 6,0oo pg/mL. The assay is a heterogeneous sandwichimmunoassay usingmagnetic_separation. Reagent 1 (R1) contains monoclonal antibody to BNP labeled with FITC and Reagent 2 (R2) contains the second monoclonal antibody to BNP (F(ab)2) conjugated to the enzyme alkaline phosphatase (ALP). The monoclonal antibodies used in the ADVIA IMS BNP assay are identical to those used in the ADVIA Centaur assay. The sandwich complex formed by the analyte and the antibody conjugates is captured by the magnetic particles so that the BNP concentration in the sample can be measured in terms of enzyme activity. The substrate used for this assay is a dioxetane phosphate derivative， which is dephosphorylated by ALP resulting in photon emission. Luminescence is measured by a photomultiplier tube. The dose response curve is proportional to the analyte concentration in sample.

The Centaur BNP Master Curve Material (MCM) (part number 02815905) will be used as the calibrators (six levels) for the ADVIA IMS BNP assay.The controls used in the ADVIA IMS BNP assay, QC BNP 1, 2, 3 (REF 02817045)，are existing Bayer Centaur products consisting of three levels of lyophilized controls.The controls contain various concentrations of BNP in bufered sodium caseinate with preservative.

# 5. Intended Use

For in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA IMS? System. This assay is indicated for the measurement of plasma BNP as an aid in the diagnosis and assessment of the severity of heart failure. In patients with acute coronary syndromes (ACS)， this test， in conjunction with other known risk factors, can also be used to predict survival as well as to predict the likelihood of future heart failure. This assay is not intended for use on any other system.

# 6. Similarities and Differences between ADVIA? IMSTM BNP assay and Bayer Centaur? BNP assay:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ADVIA IMSBNPassay</td><td rowspan=1 colspan=1>ADVIA Centaur BNP assay(predicate device)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Summary</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Principle</td><td rowspan=1 colspan=1>Heterogeneous SandwichMagnetic Separation Assay</td><td rowspan=1 colspan=1>Heterogeneous SandwichMagnetic Separation Assay</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Two liquid reagents containedin system specific packaging</td><td rowspan=1 colspan=1>Two liquid reagents containedin system specific packaging</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2-8℃</td><td rowspan=1 colspan=1>2-8℃</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Precautions</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Similar</td></tr><tr><td rowspan=1 colspan=1>Indications ofDeterioration</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>PerformanceCharacteristics</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Limitations</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Parameters</td><td rowspan=1 colspan=1>Multi-point calibration,sandwich immunoassay andsystem specific parameters</td><td rowspan=1 colspan=1>Multi-point calibration,sandwich immunoassay andsystem specific parameters</td></tr></table>

# 7. Performance summary:

a)Imprecision:

<table><tr><td rowspan=1 colspan=2>ADVIA IMS</td></tr><tr><td rowspan=1 colspan=1>Level(pg/mL)</td><td rowspan=1 colspan=1>TotalCV(%)</td></tr><tr><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>716</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>2660</td><td rowspan=1 colspan=1>1.8</td></tr></table>

<table><tr><td rowspan=1 colspan=2>ADVIA Centaur</td></tr><tr><td rowspan=1 colspan=1>Level(pg/mL)</td><td rowspan=1 colspan=1>TotalCV(%)</td></tr><tr><td rowspan=1 colspan=1>48.5</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>458</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>1736</td><td rowspan=1 colspan=1>2.9</td></tr></table>

b).Correlation:

<table><tr><td rowspan=1 colspan=1>Specimen type</td><td rowspan=1 colspan=1>ComparisonSystem (X)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Syx(pg/mL)</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>SampleRange(pg/mL)</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma</td><td rowspan=1 colspan=1>ADVIACentaur</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>0.990 * X + 4.37</td><td rowspan=1 colspan=1>111.7</td><td rowspan=1 colspan=1>0.992</td><td rowspan=1 colspan=1>4 to 4531</td></tr></table>

(Y= ADVIA IMS, $\mathsf { X } \equiv$ comparison system)

c） Interfering substances:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Interference Conc.</td><td rowspan=1 colspan=2>Recovery(pg/mL）</td><td rowspan=2 colspan=1>%Deviation</td></tr><tr><td rowspan=1 colspan=1>Interference</td><td rowspan=1 colspan=1>mg/dL</td><td rowspan=1 colspan=1>Expected Observed</td><td rowspan=1 colspan=1>Expected Observed</td></tr><tr><td rowspan=2 colspan=1>Albumin</td><td rowspan=2 colspan=1>7,000</td><td rowspan=1 colspan=1>145.3</td><td rowspan=1 colspan=1>131.5</td><td rowspan=1 colspan=1>-9.46</td></tr><tr><td rowspan=1 colspan=1>407.5</td><td rowspan=1 colspan=1>377.9</td><td rowspan=1 colspan=1>-7.27</td></tr><tr><td rowspan=2 colspan=1>Bilirubin</td><td rowspan=2 colspan=1>25</td><td rowspan=1 colspan=1>79.4</td><td rowspan=1 colspan=1>80.6</td><td rowspan=1 colspan=1>1.50</td></tr><tr><td rowspan=1 colspan=1>366.1</td><td rowspan=1 colspan=1>356.4</td><td rowspan=1 colspan=1>-2.65</td></tr><tr><td rowspan=2 colspan=1>Cholesterol</td><td rowspan=2 colspan=1>1,000</td><td rowspan=1 colspan=1>133.8</td><td rowspan=1 colspan=1>139.5</td><td rowspan=1 colspan=1>4.26</td></tr><tr><td rowspan=1 colspan=1>352.8</td><td rowspan=1 colspan=1>383.6</td><td rowspan=1 colspan=1>8.73</td></tr><tr><td rowspan=2 colspan=1>Creatinine</td><td rowspan=2 colspan=1>2.5</td><td rowspan=1 colspan=1>99.2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>0.76</td></tr><tr><td rowspan=1 colspan=1>427.0</td><td rowspan=1 colspan=1>419.0</td><td rowspan=1 colspan=1>-1.87</td></tr><tr><td rowspan=2 colspan=1>Hemoglobin</td><td rowspan=2 colspan=1>750</td><td rowspan=1 colspan=1>86.7</td><td rowspan=1 colspan=1>78.3</td><td rowspan=1 colspan=1>-9.68</td></tr><tr><td rowspan=1 colspan=1>402.3</td><td rowspan=1 colspan=1>366.7</td><td rowspan=1 colspan=1>-8.86</td></tr><tr><td rowspan=2 colspan=1>Triglyceride</td><td rowspan=2 colspan=1>800</td><td rowspan=1 colspan=1>86.2</td><td rowspan=1 colspan=1>83.4</td><td rowspan=1 colspan=1>-3.19</td></tr><tr><td rowspan=1 colspan=1>389.4</td><td rowspan=1 colspan=1>384.3</td><td rowspan=1 colspan=1>-1.32</td></tr><tr><td rowspan=2 colspan=1>Urea Nitrogen</td><td rowspan=2 colspan=1>200</td><td rowspan=1 colspan=1>87.7</td><td rowspan=1 colspan=1>88.9</td><td rowspan=1 colspan=1>1.34</td></tr><tr><td rowspan=1 colspan=1>380.2</td><td rowspan=1 colspan=1>382.0</td><td rowspan=1 colspan=1>0.48</td></tr><tr><td rowspan=2 colspan=1>lgG</td><td rowspan=2 colspan=1>4,600</td><td rowspan=1 colspan=1>129.3</td><td rowspan=1 colspan=1>141.2</td><td rowspan=1 colspan=1>9.15</td></tr><tr><td rowspan=1 colspan=1>398.7</td><td rowspan=1 colspan=1>435.8</td><td rowspan=1 colspan=1>9.30</td></tr></table>

d).Analytical Range:

4 pg/mL (1.1 pmol/L) to calibrator level 6 concentration (about 6000 pg/mL or 1728 pmol/L)

e） Minimum Detectable Concentration:

<table><tr><td>ADVIA IMSBNP (pg/mL)</td><td>ADVIACentaurBNP（pg/mL)</td></tr><tr><td>4</td><td>2</td></tr></table>

# f）Expected Results:

The expected values were determined from clinical studies performed for the predicate ADVIA_ Centaur BNP Test and results of the studies are included in the labeling for the ADVIA IMS BNP assay.

BNP concentrations in the Reference Group are shown in the tables below. The decision threshold was determined by the 95% confidence limit of BNP in the Reference population. The most appropriate decision threshold apparent from these distributions is 100 pg/mL. This BNP value translates into a general specificity of the test of greater than $97 \%$

# Reference Group

To establish the expected results, the circulating BNP concentration was determined from 1521 individuals without heart failure (785 women and 736 men). This population included apparently healthy individuals and individuals with hypertension, diabetes，renal insuficiency， and chronic obstructive pulmonarv disease.The descriptive statistics for BNP concentrations in the population without heart failure are shown in the following tables. These values are representative of the results obtained from clinical studies.

<table><tr><td rowspan=1 colspan=1>Al</td><td rowspan=1 colspan=6>Age Group</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>&lt;45years</td><td rowspan=1 colspan=1>45-54years</td><td rowspan=1 colspan=1>55-64years</td><td rowspan=1 colspan=1>65-74years</td><td rowspan=1 colspan=1>75+years</td></tr><tr><td rowspan=1 colspan=1>Mean, pg/mL</td><td rowspan=1 colspan=1>23.2</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>15.6</td><td rowspan=1 colspan=1>19.5</td><td rowspan=1 colspan=1>28.3</td><td rowspan=1 colspan=1>60.3</td></tr><tr><td rowspan=1 colspan=1>SD, pg/mL</td><td rowspan=1 colspan=1>32.5</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>15.9</td><td rowspan=1 colspan=1>22.6</td><td rowspan=1 colspan=1>25.4</td><td rowspan=1 colspan=1>73.0</td></tr><tr><td rowspan=1 colspan=1>Median,pg/mL</td><td rowspan=1 colspan=1>14.5</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>13.8</td><td rowspan=1 colspan=1>22.1</td><td rowspan=1 colspan=1>43.7</td></tr><tr><td rowspan=1 colspan=1>95 Percentile, pg/mL</td><td rowspan=1 colspan=1>70.8</td><td rowspan=1 colspan=1>33.3</td><td rowspan=1 colspan=1>46.7</td><td rowspan=1 colspan=1>53.2</td><td rowspan=1 colspan=1>72.3</td><td rowspan=1 colspan=1>176</td></tr><tr><td rowspan=1 colspan=1>% &lt;100 pg/mL</td><td rowspan=1 colspan=1>97.4</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>98.8</td><td rowspan=1 colspan=1>97.0</td><td rowspan=1 colspan=1>85.5</td></tr><tr><td rowspan=1 colspan=1>Minimum， pg/mL</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td></tr><tr><td rowspan=1 colspan=1>Maximum， pg/mL</td><td rowspan=1 colspan=1>576</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>286</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>576</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>1521</td><td rowspan=1 colspan=1>317</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>403</td><td rowspan=1 colspan=1>365</td><td rowspan=1 colspan=1>145</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Males</td><td rowspan=1 colspan=6>Age Group</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Al</td><td rowspan=1 colspan=1>&lt;45years</td><td rowspan=1 colspan=1>45-54years</td><td rowspan=1 colspan=1>55-64years</td><td rowspan=1 colspan=1>65-74years</td><td rowspan=1 colspan=1>75 +years</td></tr><tr><td rowspan=1 colspan=1>Mean, pg/mL</td><td rowspan=1 colspan=1>17.9</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>14.5</td><td rowspan=1 colspan=1>25.8</td><td rowspan=1 colspan=1>41.9</td></tr><tr><td rowspan=1 colspan=1>SD, pg/mL</td><td rowspan=1 colspan=1>22.9</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>11.8</td><td rowspan=1 colspan=1>13.9</td><td rowspan=1 colspan=1>25.1</td><td rowspan=1 colspan=1>48.8</td></tr><tr><td rowspan=1 colspan=1>Median, pg/mL</td><td rowspan=1 colspan=1>11.3</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>17.8</td><td rowspan=1 colspan=1>26.1</td></tr><tr><td rowspan=1 colspan=1>95 Percentile, pg/mL</td><td rowspan=1 colspan=1>54.3</td><td rowspan=1 colspan=1>29.4</td><td rowspan=1 colspan=1>32.8</td><td rowspan=1 colspan=1>38.8</td><td rowspan=1 colspan=1>67.6</td><td rowspan=1 colspan=1>121</td></tr><tr><td rowspan=1 colspan=1>% &lt;100 pg/mL</td><td rowspan=1 colspan=1>98.6</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>99.5</td><td rowspan=1 colspan=1>96.8</td><td rowspan=1 colspan=1>94.6</td></tr><tr><td rowspan=1 colspan=1>Minimum， pg/mL</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td></tr><tr><td rowspan=1 colspan=1>Maximum， pg/mL</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>56.6</td><td rowspan=1 colspan=1>88.9</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>151</td><td rowspan=1 colspan=1>250</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>736</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>223</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>56</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Females</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Age Group</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>AIT</td><td rowspan=1 colspan=1>&lt;45years</td><td rowspan=1 colspan=1>45-54years</td><td rowspan=1 colspan=1>55-64years</td><td rowspan=1 colspan=1>65-74years</td><td rowspan=1 colspan=1>75 +years</td></tr><tr><td rowspan=1 colspan=1>Mean, pg/mL</td><td rowspan=1 colspan=1>28.1</td><td rowspan=1 colspan=1>13.8</td><td rowspan=1 colspan=1>19.8</td><td rowspan=1 colspan=1>25.6</td><td rowspan=1 colspan=1>31.0</td><td rowspan=1 colspan=1>71.9</td></tr><tr><td rowspan=1 colspan=1>SD, pg/mL</td><td rowspan=1 colspan=1>38.8</td><td rowspan=1 colspan=1>14.6</td><td rowspan=1 colspan=1>18.0</td><td rowspan=1 colspan=1>29.0</td><td rowspan=1 colspan=1>25.5</td><td rowspan=1 colspan=1>82.9</td></tr><tr><td rowspan=1 colspan=1>Median,pg/mL</td><td rowspan=1 colspan=1>18.5</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>14.8</td><td rowspan=1 colspan=1>19.4</td><td rowspan=1 colspan=1>25.7</td><td rowspan=1 colspan=1>54.3</td></tr><tr><td rowspan=1 colspan=1>95 Percentile,pg/mL</td><td rowspan=1 colspan=1>86.1</td><td rowspan=1 colspan=1>35.9</td><td rowspan=1 colspan=1>56.7</td><td rowspan=1 colspan=1>75.5</td><td rowspan=1 colspan=1>72.9</td><td rowspan=1 colspan=1>167</td></tr><tr><td rowspan=1 colspan=1>% &lt; 100 pg/mL</td><td rowspan=1 colspan=1>96.3</td><td rowspan=1 colspan=1>99.5</td><td rowspan=1 colspan=1>99.3</td><td rowspan=1 colspan=1>97.8</td><td rowspan=1 colspan=1>97.1</td><td rowspan=1 colspan=1>79.8</td></tr><tr><td rowspan=1 colspan=1>Minimum， pg/mL</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td></tr><tr><td rowspan=1 colspan=1>Maximum, pg/mL</td><td rowspan=1 colspan=1>576</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>286</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>576</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>785</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>151</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>177</td><td rowspan=1 colspan=1>89</td></tr></table>

# Patients with Heart Failure

To establish the expected results for the ADVIA Centaur BNP assay in individuals with heart failure， plasma samples were obtained from 722 patients diagnosed with heart failure (264 women and 458 men). The descriptive statistics for BNP concentrations in patients with heart failure are presented in_the following tables. These values are representative of the results obtained from clinical studies. Each laboratory should establish a reference range representing the patient population being evaluated. In addition, laboratories should be aware of their respective institution's current practice for the evaluation of heart failure.

# Heart Failure Population - All

<table><tr><td rowspan=1 colspan=6>NYHAFunctional ClassAlI</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>AlI</td><td rowspan=1 colspan=1>NYHA1</td><td rowspan=1 colspan=1>NYHAII</td><td rowspan=1 colspan=1>NYHA1II1</td><td rowspan=1 colspan=1>NYHA IV</td></tr><tr><td rowspan=1 colspan=1>Mean, pg/mL</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>1134</td></tr><tr><td rowspan=1 colspan=1>SD,pg/mL</td><td rowspan=1 colspan=1>711</td><td rowspan=1 colspan=1>347</td><td rowspan=1 colspan=1>402</td><td rowspan=1 colspan=1>576</td><td rowspan=1 colspan=1>1141</td></tr><tr><td rowspan=1 colspan=1>Median, pg/mL</td><td rowspan=1 colspan=1>262</td><td rowspan=1 colspan=1>64.3</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>355</td><td rowspan=1 colspan=1>843</td></tr><tr><td rowspan=1 colspan=1>5 percentile, pg/mL</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>21.1</td><td rowspan=1 colspan=1>109</td></tr><tr><td rowspan=1 colspan=1>95 percentile，pg/mL</td><td rowspan=1 colspan=1>1873</td><td rowspan=1 colspan=1>772</td><td rowspan=1 colspan=1>999</td><td rowspan=1 colspan=1>1696</td><td rowspan=1 colspan=1>3157</td></tr><tr><td rowspan=1 colspan=1>% &gt; 100 pg/mL</td><td rowspan=1 colspan=1>72.6</td><td rowspan=1 colspan=1>43.1</td><td rowspan=1 colspan=1>58.7</td><td rowspan=1 colspan=1>82.0</td><td rowspan=1 colspan=1>95.8</td></tr><tr><td rowspan=1 colspan=1>Minimum，pg/mL</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Maximum， pg/mL</td><td rowspan=1 colspan=1>6989</td><td rowspan=1 colspan=1>2310</td><td rowspan=1 colspan=1>3107</td><td rowspan=1 colspan=1>4052</td><td rowspan=1 colspan=1>6989</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>722</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>242</td><td rowspan=1 colspan=1>289</td><td rowspan=1 colspan=1>119</td></tr></table>

# Heart Failure Population - Males

<table><tr><td rowspan=1 colspan=6>NYHA Functional Class</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Al</td><td rowspan=1 colspan=1>NYHA1</td><td rowspan=1 colspan=1>NYHAII</td><td rowspan=1 colspan=1>NYHA三</td><td rowspan=1 colspan=1>NYHA IV</td></tr><tr><td rowspan=1 colspan=1>Mean, pg/mL</td><td rowspan=1 colspan=1>518</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>308</td><td rowspan=1 colspan=1>542</td><td rowspan=1 colspan=1>1214</td></tr><tr><td rowspan=1 colspan=1>SD, pg/mL</td><td rowspan=1 colspan=1>726</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>475</td><td rowspan=1 colspan=1>588</td><td rowspan=1 colspan=1>1200</td></tr><tr><td rowspan=1 colspan=1>Median, pg/mL</td><td rowspan=1 colspan=1>245</td><td rowspan=1 colspan=1>77.7</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>339</td><td rowspan=1 colspan=1>950</td></tr><tr><td rowspan=1 colspan=1>5 percentile,pg/mL</td><td rowspan=1 colspan=1>10.7</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>23.2</td><td rowspan=1 colspan=1>71.5</td></tr><tr><td rowspan=1 colspan=1>95 percentile, pg/mL</td><td rowspan=1 colspan=1>1946</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>1280</td><td rowspan=1 colspan=1>1852</td><td rowspan=1 colspan=1>3157</td></tr><tr><td rowspan=1 colspan=1>% &gt; 100 pg/mL</td><td rowspan=1 colspan=1>72.9</td><td rowspan=1 colspan=1>44.7</td><td rowspan=1 colspan=1>61.3</td><td rowspan=1 colspan=1>81.4</td><td rowspan=1 colspan=1>93.9</td></tr><tr><td rowspan=1 colspan=1>Minimum, pg/mL</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>33.7</td></tr><tr><td rowspan=1 colspan=1>Maximum, pg/mL</td><td rowspan=1 colspan=1>6989</td><td rowspan=1 colspan=1>552</td><td rowspan=1 colspan=1>3107</td><td rowspan=1 colspan=1>3503</td><td rowspan=1 colspan=1>6989</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>458</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>194</td><td rowspan=1 colspan=1>66</td></tr></table>

# Heart Failure Population - Females

<table><tr><td rowspan=1 colspan=6>NYHAFunctional Class</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>AI</td><td rowspan=1 colspan=1>NYHA1</td><td rowspan=1 colspan=1>NYHAII</td><td rowspan=1 colspan=1>NYHA1III</td><td rowspan=1 colspan=1>NYHAIV</td></tr><tr><td rowspan=1 colspan=1>Mean, pg/mL</td><td rowspan=1 colspan=1>482</td><td rowspan=1 colspan=1>285</td><td rowspan=1 colspan=1>207</td><td rowspan=1 colspan=1>492</td><td rowspan=1 colspan=1>1034</td></tr><tr><td rowspan=1 colspan=1>SD, pg/mL</td><td rowspan=1 colspan=1>687</td><td rowspan=1 colspan=1>551</td><td rowspan=1 colspan=1>228</td><td rowspan=1 colspan=1>556</td><td rowspan=1 colspan=1>1068</td></tr><tr><td rowspan=1 colspan=1>Median, pg/mL</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>62.5</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>355</td><td rowspan=1 colspan=1>779</td></tr><tr><td rowspan=1 colspan=1>5 percentile, pg/mL</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9.5</td><td rowspan=1 colspan=1>15.9</td><td rowspan=1 colspan=1>115</td></tr><tr><td rowspan=1 colspan=1>95 percentile, pg/mL</td><td rowspan=1 colspan=1>1575</td><td rowspan=1 colspan=1>1447</td><td rowspan=1 colspan=1>552</td><td rowspan=1 colspan=1>1518</td><td rowspan=1 colspan=1>2970</td></tr><tr><td rowspan=1 colspan=1>% &gt; 100 pg/mL</td><td rowspan=1 colspan=1>72.0</td><td rowspan=1 colspan=1>40.0</td><td rowspan=1 colspan=1>54.3</td><td rowspan=1 colspan=1>83.2</td><td rowspan=1 colspan=1>98.1</td></tr><tr><td rowspan=1 colspan=1>Minimum, pg/mL</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>&lt;2</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Maximum， pg/mL</td><td rowspan=1 colspan=1>5845</td><td rowspan=1 colspan=1>2310</td><td rowspan=1 colspan=1>1231</td><td rowspan=1 colspan=1>4052</td><td rowspan=1 colspan=1>5845</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>264</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>53</td></tr></table>

These results show that there is a relationship between the severity of the clinical signs_and_symptoms of heart failure and the median BNP concentrations, demonstrating that the assay can be used as_an aid in the diagnosis of all degrees of heart failure severity, including asymptomatic patients.

Date

# JUN13 2005

Mr.Andres Holle Manger,Regulatory Affairs Bayer HealthCare LLC 511Benedict Avenue Tarrytown,NY 10591

Re: k051265 Trade/Device Name: B-type Natriuretic Peptide (BNP) Assay for the ADVIA IMS Regulation Number: 21 CFR 862.1117 Regulation Name: B-type natriuretic peptide test system Regulatory Class: Class II Product Code: NBC Dated:May 12,2005 Received:May 17,2005

Dear Mr. Holle:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28,1976,the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food,Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21,Code of Federal Regulations (CFR),Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements,including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This leter wil allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Ofce of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled,"Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Carol C. Benson, M.A.   
Acting Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510)Numbern)K65

Device Name: B-type Natriuretic Peptide (BNP) Assay for the ADVIA IMS

Indications for Use:

The Bayer ADViA IMS BNP method is for in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA IMS $\textsuperscript { \textregistered }$ System. This assay is indicated for the measurement of plasma BNP as an aid in the diagnosis and assessment of the severity of heart failure. In patients with acute coronary syndromes (ACS), this test, in conjunction with other known risk factors, can also be used to predict survival as well as to predict the likelihood of future heart failure. This assay is not intended for use on any other system.

Concurrence of CDRH,Office of In Vitro Diagnostic Devices (OIVD)

![](images/48b7b49a9977c3bbbed8031682d07736dc3c8ed2d067a3b4adce3c956802294b.jpg)

Page1of_1_

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k)_K051265